A prospective observational study to evaluate a possible relationship between vitamin K antagonist therapy and risk of peripheral arterial disease in patients with type 2 diabetes

Documenti analoghi

• Prediction of heart failure as the first major cardiovascular disease event in type 2 diabetes
  di: Julian W. Sacre, et al.
  Pubblicazione: (2026)
• Aldosterone synthase inhibitor ( BI 690517) therapy for people with diabetes and albuminuric chronic kidney disease: A multicentre, randomized, double‐blind, placebo‐controlled, Phase I trial
  di: Stefan R. Bornstein, et al.
  Pubblicazione: (2024)
• Methylglyoxal‐glycated apolipoproteins A‐I and A‐ II are associated with new‐onset diabetes in individuals with prediabetes
  di: Chloé Chevalier, et al.
  Pubblicazione: (2026)
• Empagliflozin mitigates metabolic dysfunction‐associated steatotic liver disease by reducing de novo lipogenesis in a mouse model of lipoatrophic diabetes
  di: Sarra Smati, et al.
  Pubblicazione: (2024)
• Impact of glucagon‐like peptide‐1 receptor agonism‐based therapies on limb outcomes in peripheral artery disease and type 2 diabetes: An updated systematic review and meta‐analysis
  di: Deep Dutta, et al.
  Pubblicazione: (2025)